-
1
Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan
Published 2025-07-01Subjects:Article -
2
Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma
Published 2025-07-01Subjects: “…Adjuvant immunotherapy…”
Get full text
Article -
3
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
Published 2025-07-01Subjects: “…Adjuvant immunotherapy…”
Get full text
Article -
4
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
Published 2025-01-01Subjects: Get full text
Article -
5
Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
Published 2025-04-01Subjects: “…adjuvant immunotherapy…”
Get full text
Article -
6
Eligibility and workload implications of adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction (ESO/GEJ) cancer
Published 2025-03-01Subjects: Get full text
Article -
7
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
Published 2024-12-01Subjects: Get full text
Article -
8
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
Published 2025-06-01Subjects: Get full text
Article -
9
-
10
Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
Published 2025-01-01Subjects: “…adjuvant immunotherapy…”
Get full text
Article -
11
The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer
Published 2025-04-01Subjects: Get full text
Article